DNLI - Why Denali Therapeutics Stock Is Sinking Today
Shares of Denali Therapeutics (NASDAQ: DNLI) had sunk 11.2% as of 12:02 p.m. EDT on Monday. The decline came after the company presented interim results on Sunday from a phase 1/2 study evaluating experimental enzyme replacement therapy DNL310 in treating the rare neurodegenerative disorder Hunter syndrome.
You'd probably expect that Denali's phase 1/2 interim results would be bad considering how the biotech stock fell. But the company touted the interim data as "positive." The reality is that there was both good and bad news with the latest results.
Image source: Getty Images.
For further details see:
Why Denali Therapeutics Stock Is Sinking Today